A recent survey of physicians revealed that 17% of doctors with personal experience with cancer were more likely than those without to act against established guidelines to recommend that low-risk women receive ovarian cancer screening.
Broad-based genomic sequencing, while useful in identifying tumor mutations in patients with non-small cell lung cancer (NSCLC), may not improve survival outcomes when compared to routine genomic testing.
While patients may feel a sense of urgency in making a treatment decision, it’s important for patients to assess their own feelings about their goals for treatment.
Attempting to learn and process large amounts of complex information after a diagnosis of pancreatic cancer can leave anyone feeling lost. So where should you turn? Start with Patient Central.
Getting organized can help patients and their loved ones take control and better understand their options after a cancer diagnosis.
Adverse events (AEs) associated with brentuximab vedotin (BV; Adcetris) - used to treat hematological malignancies - may be serious, and nurses need to understand what they are, monitor for them, and treat them promptly.
Hundreds of oncology professionals will gather in Phoenix, Arizona, to share best practices and creative approaches that address the most pressing issues facing cancer programs in communities around the country.
The FDA has approved the kinase inhibitor ibrutinib (Imbruvica) for use in combination with rituximab (Rituxan) for the treatment of patients with Waldenström macroglobulinemia, a form of non-Hodgkin lymphoma.
Patients who report higher satisfaction with their physicians’ communication with them also were more likely to receive more efficient care with fewer office visits and better health outcomes at lower costs.
African-American and Caucasian patients with metastatic castration-resistant prostate cancer (mCRPC) demonstrated similar overall survival (OS) rates, according to study results presented at the 2018 ASCO Annual Meeting.
The FDA has granted a priority review to the immunostimulatory monoclonal antibody elotuzumab (Empliciti) for use in combination with pomalidomide (Pomalyst) and low-dose dexamethasone (EPd) to treat patients with relapsed/refractory multiple myeloma (MM) who have received 2 or more prior therapies, including lenalidomide (Revlimid) and a proteasome inhibitor.
A year after the first CAR T-cell therapy was approved to treat pediatric patients with relapsed and/or refractory CD19-positive acute lymphoblastic leukemia (ALL), researchers have issued guidelines to help healthcare professionals recognize and treat the associated adverse events (AEs) from this treatment.
CURE Media Group, the nation’s leading digital and print media enterprise dedicated to patients and survivors of cancer, welcomes The Biden Cancer Initiative to the Strategic Alliance Partnership (SAP) program.
The FDA has granted a full approval to the combination use of pembrolizumab (Keytruda) plus standard chemotherapy in the first-line setting for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC).
Canadian researchers recently created the Managing Cancer and Living Meaningfully (CALM) intervention for patients with advanced cancer who had a life expectancy of at least 1 year to address the need for supportive psychotherapy interventions that are individualized to the patient, brief, and easy to implement.
The addition of tumor treating fields (TTF), an antimitotic therapy that delivers continuous low-intensity electrical fields to the tumor region, to weekly paclitaxel (Taxol) appeared safe in the treatment of patients with platinum-resistant ovarian cancer.
The FDA has granted an accelerated approval to nivolumab (Opdivo) for the treatment of patients with small cell lung cancer (SCLC) whose disease has progressed after platinum-based chemotherapy and 1 other line of therapy.
Enfortumab vedotin, an antibody-drug conjugate, showed promise as a post-immunotherapy treatment of patients with locally advanced or metastatic urothelial cancer, according to Jonathan E. Rosenberg, MD.
The Food and Drug Administration (FDA) approved a supplemental new drug application for the multikinase inhibitor lenvatinib (Lenvima) for first-line treatment of patients with unresectable hepatocellular carcinoma.
Late effects from treatment of central nervous system (CNS) tumors, such as cognitive impairment and physical performance, may hinder full functional and social independence among adult survivors, according to findings published in the Journal of Clinical Oncology.
Over the last few years, treatments for patients with metastatic hormone receptor (HR)-positive breast cancer have evolved rapidly. As changes in care continue to progress, nurses need to understand these treatment options, and where the research may take the field in the future.
The annual signature event has now raised more than $100 million for the V Foundation.
Nurses, doctors, social workers, and the rest of the medical team and facility staff at treatment centers have the ability to bring hope, gratitude, peace, and love, all part of spirituality—to their patients.
The FDA has granted a priority review designation to a biologics license application (BLA) for SL-401 (tagraxofusp, Elzonris) for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to Stemline Therapeutics, the developer of the novel stemness inhibitor.
Men are reported to be less likely to receive palliative care, according to research led by Fahad Saeed, MD, from the University of Rochester Medical Center in Rochester, New York, and colleagues.
As abemaciclib (Verzenio) has emerged as a promising agent for patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, the oncology nurse is now a key factor for these patients, according to Paula Fulgham, RN, OCN.
The favored use of immune checkpoint inhibitors in oncology has led to an increase in immune-related adverse events (IRAEs), which if not managed properly, can be life-threatening.
Distinguished nurse scientist, professor, and associate dean of research and scholarship leaves a lasting legacy.
CURE magazine, the nation’s leading consumer digital and print media enterprise focused on patients with cancer, was recently named a finalist in four categories in the Folio: Eddie and Ozzie Awards, the most prestigious and most inclusive awards program in the publishing community.
The FDA has approved the monoclonal antibody mogamulizumab-kpkc (Poteligeo) for the treatment of patients with 2 rare subtypes of cutaneous T-cell lymphoma, mycosis fungoides or Sézary syndrome, who have received at least 1 prior systemic therapy.
